Tags

Type your tag names separated by a space and hit enter

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Bone Marrow Transplant. 2000 Mar; 25(6):665-72.BM

Abstract

In order to evaluate the risk of cytomegalovirus (CMV) associated disease after allogeneic stem cell transplantation (SCT), 158 consecutive patients at risk for infection were analyzed. BMT was performed in 101 patients and peripheral blood stem cell transplantation (PBSCT) in 57 patients. CMV antigenemia was found in 57 cases (56%) after BMT and 27 cases (47%) after PBSCT, respectively. CMV antigenemia resistant to a 14-day course of GCV was found in 26 patients (26%) after BMT but in only four patients (7%) after PBSCT (P < 0.01). Eighteen patients (11%) developed CMV disease, 14 post BMT and four post PBSCT. Lethal CMV-related interstitial pneumonia (CMV-IP) occurred in 13 cases of whom 12 patients were bone marrow recipients (P = 0.04). The subgroup of seronegative patients with a CMV seropositive donor had a significantly lower risk of developing CMV antigenemia, GCV-resistant CMV antigenemia (P < 0.01) and CMV-related disease (P = 0.01). In conclusion, the incidence of persistent CMV antigenemia and CMV-IP was significantly reduced when allogeneic transplantation was performed with peripheral blood stem cells instead of bone marrow. These findings suggest that our previous in vitro data on improved immune reconstitution after allogeneic PBSCT as compared to allogeneic BMT have clinical relevance.

Authors+Show Affiliations

Department of Bone Marrow Transplantation and Internal Medicine (Tumor Research), Biometry and Epidemiology, University Hospital of Essen, Essen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

10734302

Citation

Trenschel, R, et al. "Reduced Risk of Persisting Cytomegalovirus Pp65 Antigenemia and Cytomegalovirus Interstitial Pneumonia Following Allogeneic PBSCT." Bone Marrow Transplantation, vol. 25, no. 6, 2000, pp. 665-72.
Trenschel R, Ross S, Hüsing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 2000;25(6):665-72.
Trenschel, R., Ross, S., Hüsing, J., Ottinger, H., Elmaagacli, A., Roggendorf, M., Schaefer, U. W., & Runde, V. (2000). Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplantation, 25(6), 665-72.
Trenschel R, et al. Reduced Risk of Persisting Cytomegalovirus Pp65 Antigenemia and Cytomegalovirus Interstitial Pneumonia Following Allogeneic PBSCT. Bone Marrow Transplant. 2000;25(6):665-72. PubMed PMID: 10734302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. AU - Trenschel,R, AU - Ross,S, AU - Hüsing,J, AU - Ottinger,H, AU - Elmaagacli,A, AU - Roggendorf,M, AU - Schaefer,U W, AU - Runde,V, PY - 2000/3/29/pubmed PY - 2000/5/20/medline PY - 2000/3/29/entrez SP - 665 EP - 72 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 25 IS - 6 N2 - In order to evaluate the risk of cytomegalovirus (CMV) associated disease after allogeneic stem cell transplantation (SCT), 158 consecutive patients at risk for infection were analyzed. BMT was performed in 101 patients and peripheral blood stem cell transplantation (PBSCT) in 57 patients. CMV antigenemia was found in 57 cases (56%) after BMT and 27 cases (47%) after PBSCT, respectively. CMV antigenemia resistant to a 14-day course of GCV was found in 26 patients (26%) after BMT but in only four patients (7%) after PBSCT (P < 0.01). Eighteen patients (11%) developed CMV disease, 14 post BMT and four post PBSCT. Lethal CMV-related interstitial pneumonia (CMV-IP) occurred in 13 cases of whom 12 patients were bone marrow recipients (P = 0.04). The subgroup of seronegative patients with a CMV seropositive donor had a significantly lower risk of developing CMV antigenemia, GCV-resistant CMV antigenemia (P < 0.01) and CMV-related disease (P = 0.01). In conclusion, the incidence of persistent CMV antigenemia and CMV-IP was significantly reduced when allogeneic transplantation was performed with peripheral blood stem cells instead of bone marrow. These findings suggest that our previous in vitro data on improved immune reconstitution after allogeneic PBSCT as compared to allogeneic BMT have clinical relevance. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10734302/Reduced_risk_of_persisting_cytomegalovirus_pp65_antigenemia_and_cytomegalovirus_interstitial_pneumonia_following_allogeneic_PBSCT_ L2 - https://doi.org/10.1038/sj.bmt.1702216 DB - PRIME DP - Unbound Medicine ER -